The Induction of Interleukin-6 (IL-6) and Colony-Stimulating Factors (CSFs) by FK565 and Its Thrombopoietic Activity Following in Vivo Administration
スポンサーリンク
概要
- 論文の詳細を見る
The induction of macrophage colony-stimulating factor (M-CSF) in monkey plasma following administration of FK 565 was observed within 2 h of injection peaked at 4 h, and remained high after 24 h. Interleukin-6 (IL-6) and M-CSF levels increased in monkeys treated with FK565,even at doses as low as 0.01 mg/kg. Granulocyte CSF (G-CSF) levels increased slightly following a dose of 1 mg/kg, but granulocyte macrophage CSF (GM-CSF) was not detected at any doses of FK565 studied. To examine the thrombopoietic activity of FK565 in vivo, single doses of drug (0.01,0.1 or 1.0 mg/kg) were administered i.v. to cynomolgus monkeys or normal mice on day 0. The promotes platelet (PLT) count after FK565 injection decreased transiently on days 1 and 2,and then increased in a dose-dependent manner on day 5 and was still high on day 14. The experiment using anti-PLT antibody showed that the increased PLT count was not simply due to a rebound phenomenon after the transient decrease in PLT. The effect of i.v. FK565 was studied in mice myelosuppressed with a single dose of mitomycin C (MMC) (5.6 mg/kg). The fall in PLT count was suppressed on day 7 by 0.1 and 1.0 mg/kg FK565. Although intact cells or tissues are necessary for an increase in PLT following FK565 treatment, FK565 suppressed the impaired hematopoietic function seen after chemotherapy. FK565 is proposed as a drug to restore reduced neutrophil and platelet counts found in AIDS or cancer therapy.
- 社団法人日本薬学会の論文
- 1994-02-15
著者
-
大塚 一幸
藤沢薬品
-
今井 祐子
Product Development Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
佐藤 晋
藤沢薬品・開発第一研究所
-
下村 恭一
藤沢薬品・開発第一研究所
-
向阪 正信
藤沢薬品・開発第一研究所
-
前田 昌宏
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
鈴木 真吾
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
大塚 一幸
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
佐藤 晋
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
西垣 扶佐子
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
下村 恭一
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
丹羽 峰雄
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
向阪 正信
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
鈴木 真吾
Product Development Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
丹羽 峰雄
Product Development Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
前田 昌宏
Product Development Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
大塚 一幸
Product Development Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
西垣 扶佐子
Product Development Laboratories Fujisawa Pharmaceutical Co. Ltd.
関連論文
- レチノイン酸による顆粒球系分化誘導とカルシニュウリン及びイムノフィリンの動態
- 544 大腸菌HB101によるメカセルミン(IGF-1)融合蛋白の高生産
- ヒトレニンおよびヒトアンジオテンシノーゲン遺伝子導入によるヒト型高血圧トランスジェニックラットの作製
- The Induction of Interleukin-6 (IL-6) and Colony-Stimulating Factors (CSFs) by FK565 and Its Thrombopoietic Activity Following in Vivo Administration